Free Sierra Leone

Wednesday, September 21, 2016

Zortress

Zortress is a brand name of everolimus, approved by the FDA in the following formulation(s):

ZORTRESS (everolimus - tablet; oral)

Manufacturer: NOVARTIS

Approval date: April 20, 2010

Strength(s): 0.25MG, 0.5MG, 0.75MG ^[RLD]

Has a generic version of Zortress been approved?

No. There is currently no therapeutically equivalent version of Zortress available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zortress. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
Patent 5,665,772
Issued: September 9, 1997
Inventor(s): Cottens; Sylvain & Sedrani; Richard
Assignee(s): Sandoz Ltd.
Novel derivatives of rapamycin, particularly 9-deoxorapamycins, 26-dihydro-rapamycins, and 40-0-substituted and 28,40-0,0-di-substituted rapamycins, are found to have pharmaceutical utility, particularly as an immunosuppressants.
Patent expiration dates:
- September 9, 2019
  ✓
  Patent use: PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A RENAL TRANSPLANT
  ✓
  Drug substance
  ✓
  Drug product

Pharmaceutical compositions comprising rafamycin coprecipitates
Patent 6,004,973
Issued: December 21, 1999
Inventor(s): Guitard; Patrice & Haeberlin; Barbara & Link; Rainer & Richter; Friedrich
Assignee(s): Novartis AG
Disclosed are pharmaceutical compositions containing solid dispersions in the form of co-precipitates, which solid dispersions contain rapamycin and a carrier medium, and methods of treatment utilizing such pharmaceutical compositions.
Patent expiration dates:
- July 12, 2016
  ✓
  Patent use: PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A RENAL TRANSPLANT
  ✓
  Drug product

Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin
Patent 6,239,124
Issued: May 29, 2001
Inventor(s): Zenke; Gerhard & Schuurman; Hendrik & Haeberlin; Barbara & Meinzer; Armin
Assignee(s): Novartis AG
A synergistic combination of an IL-2 transcription inhibitor (e.g., cyclosporin A or FK506) and 40-O-(2-hydroxyethyl)-rapamycin is provided, which is useful in the treatment and prevention of transplant rejection and also certain autoimmune and inflammatory diseases, together with novel pharmaceutical compositions comprising an IL-2 transcription inhibitor in combination with a rapamycin, e.g., 40-O-(2-hydroxyethyl)-rapamycin.
Patent expiration dates:
- August 11, 2017
  ✓
  Patent use: PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A RENAL TRANSPLANT

O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
Patent 6,440,990
Issued: August 27, 2002
Inventor(s): Sylvain; Cottens & Richard; Sedrani
Assignee(s): Novartis AG
Novel derivatives of rapamycin, particularly 9-deoxo-rapamycins, 26-dihydro-rapamycins, and 40-O-substituted and 28,40-O,O-disubstituted rapamycins. are found to have pharmaceutical utility, particularly as immunosuppressants.
Patent expiration dates:
- September 24, 2013
  ✓
  Patent use: PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A RENAL TRANSPLANT
  ✓
  Drug product

Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin
Patent 6,455,518
Issued: September 24, 2002
Inventor(s): Gerhard; Zenke & Hendrik; Schuurman & Barbara; Haeberlin & Armin; Meinzer
Assignee(s): Novartis AG
A synergistic combination of an IL-2 transcription inhibitor (e.g., cyclosporin A or FK506) and 40-O-(2-hydroxyethyl)-rapamycin is provided, which is useful in the treatment and prevention of transplant rejection and also certain autoimmune and inflammatory diseases, together with novel pharmaceutical compositions comprising an IL-2 transcription inhibitor in combination with a rapamycin, e.g., 40-O-(2-hydroxyethyl)-rapamycin.
Patent expiration dates:
- July 29, 2017
  ✓
  Patent use: PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A RENAL TRANSPLANT

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

Exclusivity expiration dates:
- April 20, 2013 - NEW PRODUCT
- March 30, 2014 - NEW CHEMICAL ENTITY

Has a generic version of Finacea been approved?

No. There is currently no therapeutically equivalent version of Finacea available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Finacea. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Composition with azelaic acid
Patent 6,534,070
Issued: March 18, 2003
Inventor(s): Patrick; Franke & Clemens; Günther & Jutta; Riedl
Assignee(s): Schering Aktiengesellschaft
The invention relates to a pharmaceutical composition having the following constituents: azelaic acid, polyacrylic acid, triacylglyceride, propylene glycol, polysorbate, soya lecithin, water and salts. The composition is a hydrogel which is suited for the treatment of rosacea, presbyderma, melasma or skin irritations.
Patent expiration dates:
- November 18, 2018

Has a generic version of Zaroxolyn been approved?

Yes. The following products are equivalent to Zaroxolyn:

metolazone tablet; oral

Manufacturer: MYLAN

Approval date: December 23, 2003

Strength(s): 2.5MG ^[AB]

Manufacturer: MYLAN

Approval date: October 19, 2004

Strength(s): 10MG ^[AB], 5MG ^[AB]

Manufacturer: SANDOZ

Approval date: December 19, 2003

Strength(s): 10MG ^[AB], 2.5MG ^[AB], 5MG ^[AB]

Manufacturer: TEVA

Approval date: December 24, 2003

Strength(s): 10MG ^[AB]

Manufacturer: TEVA

Approval date: January 6, 2004

Strength(s): 2.5MG ^[AB]

Manufacturer: TEVA

Approval date: March 1, 2004

Strength(s): 5MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zaroxolyn. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Zaroxolyn.

Has a generic version of Zosyn been approved?

A generic version of Zosyn has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Zosyn and have been approved by the FDA:

PIPERACILLIN AND TAZOBACTAM (piperacillin sodium; tazobactam sodium injectable; injection)

Manufacturer: AUROBINDO PHARMA LTD

Approval date: May 23, 2011

Strength(s): EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL ^[AP], EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL ^[AP], EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL ^[AP]

Manufacturer: HOSPIRA INC

Approval date: September 15, 2009

Strength(s): EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL ^[AP], EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL ^[AP], EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL ^[AP], EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL ^[AP]

Manufacturer: INSTITUTO BIOCHEMICO

Approval date: May 31, 2011

Strength(s): EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL ^[AP], EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL ^[AP], EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL ^[AP], EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL ^[AP]

Manufacturer: SANDOZ

Approval date: October 21, 2010

Strength(s): EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL ^[AP], EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL ^[AP], EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL ^[AP], EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL ^[AP], EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL ^[AP], EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL ^[AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zosyn. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Compositions containing pipercillin and tazobactam useful for injection
Patent 6,900,184
Issued: May 31, 2005
Inventor(s): Cohen; Jonathan Marc & Shah; Syed M. & Ofslager; Christian Luther & Fawzi; Mahdi
Assignee(s): Wyeth Holdings Corporation
The invention pertains to pharmaceutical compositions of Zosyn® piperacillin with tazobactam in the presence of a buffer, preferably citrate, a particulate formation inhibitor, preferably EDTA optionally an aminoglycoside which when frozen and thawed or lyophilized and reconstituted reform a solution which has decreased particulate formation.
Patent expiration dates:
- April 14, 2023
  ✓
  Patent use: METHOD OF TREATING BACTERIAL INFECTIONS
  ✓
  Drug product

Compositions containing piperacillin and tazobactam useful for injection
Patent 7,915,229
Issued: March 29, 2011
Inventor(s): Cohen; Jonathan Marc & Shah; Syed Muzafar & Ofslager; Christian Luther & Fawzi; Mahdi Bakir
Assignee(s): Wyeth Holdings Corporation
An aminocarboxylic acid chelating agent, preferably EDTA, or a salt thereof has been found to be useful for inhibiting particulate formation in piperacillin/tazobactam parenteral combinations. The composition may also contain a buffer, preferably citrate, and optionally an aminoglycoside. The product may be in the form of a frozen composition that can be thawed for use. The product may also be in the form of a cryodesiccated powder that can be reconstituted by addition of an aqueous vehicle to reform a solution.
Patent expiration dates:
- April 14, 2023
  ✓
  Drug product

Has a generic version of Fareston been approved?

No. There is currently no therapeutically equivalent version of Fareston available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Fareston. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Fareston.

Has a generic version of Zantac 150 been approved?

Yes. The following products are equivalent to Zantac 150:

ranitidine hydrochloride tablet; oral

Manufacturer: AMNEAL PHARMS NY

Approval date: October 13, 2006

Strength(s): EQ 150MG BASE ^[AB]

Manufacturer: APOTEX

Approval date: September 12, 1997

Strength(s): EQ 150MG BASE ^[AB]

Manufacturer: DR REDDYS LABS INC

Approval date: July 27, 2005

Strength(s): EQ 150MG BASE ^[AB]

Manufacturer: GLENMARK GENERICS

Approval date: November 19, 2008

Strength(s): EQ 150MG BASE ^[AB]

Manufacturer: IVAX SUB TEVA PHARMS

Approval date: September 30, 1998

Strength(s): EQ 150MG BASE ^[AB]

Manufacturer: MYLAN

Approval date: August 22, 1997

Strength(s): EQ 150MG BASE ^[AB]

Manufacturer: PAR PHARM

Approval date: January 28, 1999

Strength(s): EQ 150MG BASE ^[AB]

Manufacturer: SANDOZ

Approval date: August 29, 1997

Strength(s): EQ 150MG BASE ^[AB]

Manufacturer: TEVA

Approval date: July 31, 1997

Strength(s): EQ 150MG BASE ^[AB]

Manufacturer: WATSON LABS

Approval date: October 20, 1997

Strength(s): EQ 150MG BASE ^[AB]

Manufacturer: WATSON LABS

Approval date: December 19, 2005

Strength(s): EQ 150MG BASE ^[AB]

Manufacturer: WOCKHARDT

Approval date: December 17, 1998

Strength(s): EQ 150MG BASE ^[AB]

Manufacturer: WOCKHARDT

Approval date: November 12, 2009

Strength(s): EQ 150MG BASE ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zantac 150. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Zantac 150.

Has a generic version of Zyvox been approved?

No. There is currently no therapeutically equivalent version of Zyvox available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zyvox. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Substituted oxazine and thiazine oxazolidinone antimicrobials
Patent 5,688,792
Issued: November 18, 1997
Inventor(s): Barbachyn; Michael R. & Brickner; Steven J. & Hutchinson; Douglas K.
Assignee(s): Pharmacia & Upjohn Company
A compound of structural Formula I: ##STR1## or pharmaceutically acceptable salts thereof wherein: X is O, S, SO, SO.sub.2, SNR.sup.10 or S(O)NR.sup.10 ; R is (a) hydrogen, (b) C.sub.1 -C.sub.8 alkyl optionally substituted with one or more of the following: F, Cl, hydroxy, C.sub.1 -C.sub.8 alkoxy, C.sub.1 -C.sub.8 acyloxy or --O--CH.sub.2 --Ph, (c) C.sub.3 -C.sub.6 cycloalkyl, (d) amino, (e) C.sub.1 -C.sub.8 alkylamino, (f) C.sub.1 -C.sub.8 dialkylamino or (g) C.sub.1 -C.sub.8 alkoxy; R.sup.1 is H, except when X is O then R.sup.1 can be H, CH.sub.3, CN, CO.sub.2 H, CO.sub.2 R or (CH.sub.2).sub.m R.sup.11 (m is 1 or 2); R.sup.2 is independently H, F or Cl; R.sup.3 is H except when X is O and R.sup.1 is CH.sub.3 then R.sup.3 can be H or CH.sub.3 ; R.sup.10 is independently H, C.sub.1 -C.sub.4 alkyl (optionally substituted with chloro, fluoro, hydroxy, C.sub.1 -C.sub.8 alkoxy, amino, C.sub.1 -C.sub.8 alkylamino, or C.sub.1 -C.sub.8 dialkylamino) or p-toluenesulfonyl; R.sup.11 is hydrogen, OH, OR, OCOR, NH.sub.2, NHCOR or N(R.sup.10).sub.2 ; and n is 0, 1 or 2. The oxazine and thiazine oxazolidinone derivatives are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including gram-positive aerobic bacteria such as multiply-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms such as Bacteroides spp. and Clostridia spp. species, and acid-fast organisms such as Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium spp.
Patent expiration dates:
- November 18, 2014
  ✓
  Patent use: TREATMENT OF MICROBIAL INFECTIONS
  ✓
  Drug substance
- November 18, 2014
  ✓
  Patent use: TREATMENT OF MICROBIAL INFECTIONS
- May 18, 2015
  ✓
  Pediatric exclusivity

Oxazolidinone tablet formulation
Patent 6,514,529
Issued: February 4, 2003
Inventor(s): Ken; Yamamoto & Homer; Lin
Assignee(s): Pharmacia & Upjohn Company
The present invention provides a compressed tablet of an antibacterial oxazolidinone agent which provides high drug load and excellent bioavailability.
Patent expiration dates:
- March 15, 2021
  ✓
  Drug product
- September 15, 2021
  ✓
  Pediatric exclusivity

Linezolid—crystal form II
Patent 6,559,305
Issued: May 6, 2003
Inventor(s): Michael S.; Bergren
Assignee(s): Pharmacia & Upjohn Company
The invention is a novel crystal form (Form II) of a known compound, linezolid which is useful as an antibacterial agent.
Patent expiration dates:
- January 29, 2021
  ✓
  Drug substance
- July 29, 2021
  ✓
  Pediatric exclusivity

Wednesday, September 21, 2016

ZORTRESS (everolimus - tablet; oral)

Has a generic version of Zortress been approved?

Related Patents

Related Exclusivities

See also...

FINACEA (azelaic acid - gel; topical)

Has a generic version of Finacea been approved?

Related Patents

See also...

ZAROXOLYN (metolazone - tablet; oral)

Has a generic version of Zaroxolyn been approved?

metolazone tablet; oral

Related Patents

See also...

ZOSYN (piperacillin sodium; tazobactam sodium - injectable; injection)

Has a generic version of Zosyn been approved?

PIPERACILLIN AND TAZOBACTAM (piperacillin sodium; tazobactam sodium injectable; injection)

Related Patents

See also...

FARESTON (toremifene citrate - tablet; oral)

Has a generic version of Fareston been approved?

Related Patents

See also...

ZANTAC 150 (ranitidine hydrochloride - tablet; oral)

Has a generic version of Zantac 150 been approved?

ranitidine hydrochloride tablet; oral

Related Patents

See also...

ZYVOX (linezolid - for suspension; oral)

ZYVOX (linezolid - injectable; injection)

ZYVOX (linezolid - tablet; oral)

Has a generic version of Zyvox been approved?

Related Patents

See also...